LINC00917: A Potential Drug Target and Biomarker (G732275)

Target Name: LINC00917

NCBI ID: G732275

LINC00917

Other Name(s): Long intergenic non-protein coding RNA 917 | long intergenic non-protein coding RNA 917

LINC00917: A Potential Drug Target and Biomarker

Introduction

LINC00917 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as having potential drug targets and biomarkers. This RNA is located between the coding regions of the gene encoding the protein ZNF21 and the gene encoding the protein hnRNAF12 , which are both part of the TGF-β pathway. The TGF-β pathway is a well-established pathway that plays a crucial role in the development and maintenance of tissues, and is involved in various cellular processes, including cell growth, differentiation, and inflammation. Therefore, targeting the TGF-β pathway and its downstream targets is a promising strategy for the development of new therapeutic approaches for various diseases.

The RNA Expression and Localization

LINC00917 is a 21.1 kilobase (kb) RNA molecule that is predominantly expressed in the brain, heart, and liver. It is located between the coding regions of the genes ZNF21 and hnRNAF12, as identified by bioinformatic analysis of RNA sequencing (RNA-seq) data. ZNF21 is a non-coding RNA molecule that is known to play a role in the regulation of cell growth, differentiation, and survival. hnRNAF12 is a coding RNA molecule that is known to be involved in the regulation of cell nuclear structure and the expression of various genes. The expression of LINC00917 is significantly regulated by the TGF-β pathway, as demonstrated by RNA-seq data.

The Potential Role of LINC00917 as a Drug Target

LINC00917 has been identified as a potential drug target due to its involvement in the TGF-β pathway. The TGF-β pathway is involved in the regulation of cellular processes that are crucial for the development and maintenance of tissues, including cell growth, differentiation, and inflammation. Therefore, targeting the TGF-β pathway and its downstream targets is a promising strategy for the development of new therapeutic approaches for various diseases.

LINC00917 has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and survival. For example, LINC00917 has been shown to be involved in the regulation of the growth and differentiation of neural cells. In addition, LINC00917 has also been shown to play a role in the regulation of the expression of genes involved in cell survival and stress response, such as Bcl2 and p53.

Furthermore, LINC00917 has also been shown to be involved in the regulation of inflammation. LINC00917 has been shown to play a role in the regulation of the expression of genes involved in inflammation and immune response, such as NF-kappa-B and transcription factor-3 ( TF-3). Therefore, targeting LINC00917 with small molecules or antibodies that can modulate its expression levels could be a promising strategy for the development of new therapeutic approaches for various inflammatory diseases.

The Potential Role of LINC00917 as a Biomarker

LINC00917 has also been identified as a potential biomarker for various diseases. For example, LINC00917 has been shown to be involved in the regulation of cellular processes that are involved in the development and progression of cancer. Therefore, targeting LINC00917 with small molecules or antibodies that can modulate its expression levels could be a promising strategy for the development of new therapeutic approaches for various cancer types.

In addition, LINC00917 has also been shown to play a role in the regulation

Protein Name: Long Intergenic Non-protein Coding RNA 917

The "LINC00917 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00917 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets